Davor Galusic

Split, 21000, Croatia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study.

Comparative Value of the Novel Age-Agnostic DIPSS-R Versus the DIPSS for Prognostication in Myelofibrosis: A Multicenter Evaluation and Reclassification Study.

Journal: Cancers
Published: May 31, 2026

Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Early Peripheral Blood WT1 Expression Predicts Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.

Journal: International journal of molecular sciences
Published: April 18, 2026

High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma.

High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma.

Journal: International journal of molecular sciences
Published: April 09, 2025

Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.

Extreme Thrombocytosis in Patients with Overt Myelofibrosis and Its Clinical Associations.

Journal: Cancers
Published: March 12, 2025

Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis.

Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis.

Journal: Journal of clinical medicine
Published: February 10, 2025

High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors.

High lymphocyte count and bleeding risk in patients with chronic lymphocytic leukemia treated with Bruton's tyrosine kinase inhibitors.

Journal: Wiener klinische Wochenschrift
Published: February 02, 2025

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?

Is There a Role for Daratumumab Retreatment in Patients with Relapsed/Refractory Multiple Myeloma?

Journal: Biomedicines
Published: December 23, 2024

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases.

Obinutuzumab in Combination with Alternative Chlorambucil Schedules in Front-Line Treatment of Chronic Lymphocytic Leukemia: A Study by KroHem, the Croatian Cooperative Group for Hematologic Diseases.

Journal: Biomedicines
Published: November 26, 2024

Carfilzomib in relapsed/refractory multiple myeloma patients - real world evidence - experiences of the Croatian cooperative group for hematologic diseases (KROHEM).

Carfilzomib in relapsed/refractory multiple myeloma patients - real world evidence - experiences of the Croatian cooperative group for hematologic diseases (KROHEM).

Journal: Cancer treatment and research communications
Published: November 20, 2024

SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.

SATB1 and p16 Expression and Prognostic Value in Croatian Hodgkin Lymphoma Patients: A Unicentric Study.

Journal: Cells
Published: July 05, 2024

Triple a score (AAA: age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis.

Triple a score (AAA: age, absolute neutrophil count and absolute lymphocyte count) and its prognostic utility in patients with overt fibrotic and prefibrotic myelofibrosis.

Journal: Annals of hematology
Published: March 11, 2024

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis.

Journal: Life (Basel, Switzerland)
Published: March 08, 2024
Showing 1-12 of 29

Last Updated: 09/26/2026